This drug delayed rheumatoid arthritis for years after treatment ended

A study found that one year of treatment with the immune-targeting drug abatacept delayed rheumatoid arthritis onset by up to four years in high-risk individuals, with benefits persisting after treatment ended. The results suggest rheumatoid arthritis may not be inevitable for those at high risk.